Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Abstract Background More and more evidence indicates sodium-glucose co-transporter 2 inhibitors (SGLT2is) may display clinical benefits for heart failure with preserved ejection fraction (HFpEF). However, the mechanisms of the action remain unclear. Methods A systematic pharmacology-based strategy w...

Full description

Bibliographic Details
Main Authors: Bo Liang, Yi Liang, Ning Gu
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Cardiovascular Disorders
Subjects:
Sodium-glucose co-transporter 2 inhibitors
Heart failure with preserved ejection fraction
Network pharmacology
Virtual screening
Molecular docking
Online Access:https://doi.org/10.1186/s12872-022-02693-8

Internet

https://doi.org/10.1186/s12872-022-02693-8

Similar Items